MA-VERACODE
15.3.2022 16:32:06 CET | Business Wire | Press release
Veracode, a leading global provider of application security solutions today announced that TA Associates (“TA”), a leading global growth private equity firm, has signed a definitive agreement to make a significant growth investment in the company. Veracode’s current majority investor, Thoma Bravo, a leading software investment firm, will retain a minority position in the business. The transaction, which values Veracode at $2.5B, is expected to be completed in Q2 2022, subject to customary closing conditions.
An eight-time leader in the Gartner Magic Quadrant for Application Security Testing, Veracode offers a comprehensive software security platform that empowers organizations to deliver secure software at scale and with unmatched speed.
"What we do has never been more crucial,” said Sam King, CEO of Veracode. “The confluence of digital transformation, software supply chain complexity, and the strengthening regulatory environment places software security firmly in the spotlight. We’re grateful for Thoma Bravo’s partnership over the last three years and look forward to our next chapter with TA. Together, we aim to accelerate our vision to deliver the most comprehensive software security platform that caters to the needs of both development teams and security teams by enabling them to build and deliver secure software at the speed that business demands.”
Under pressure by the ever-accelerating pace of digital transformation, software development teams are often forced to make tradeoffs between speed of delivery and the security of the software they deploy. Veracode’s platform balances the needs of both development and security teams by streamlining workflows to help customers ensure that software is coded securely without compromising speed while providing a comprehensive view of software security posture through powerful reporting and analytics. Collectively, Veracode customers have scanned over 53 trillion lines of code and fixed more than 71 million security flaws. With more than 2600 customers and nearly two-thirds of its revenue generated from large enterprise companies, the business has consistently outpaced growth forecasts for spending growth in application security.
“TA recognizes the strong market opportunity for Veracode, driven by the need to secure software and educate developers,” said Jason Werlin, a Managing Director at TA. "We believe Veracode's heritage and sustained leadership position, along with the breadth and depth of its portfolio, uniquely positions the company to drive the next wave of growth in the application security market. TA is excited to partner with the Veracode management team and Thoma Bravo on the next phase of the company’s journey.”
“Over the last three years, Veracode has expanded its platform, extended its market footprint, and established a clear track record of sustained innovation,” said Seth Boro, a Managing Partner at Thoma Bravo. “In today’s digital world, cybersecurity solutions are more critical than ever before, and Veracode continues to drive innovation while helping solve customers’ most complicated security needs. We are very proud of what Veracode has achieved under our majority ownership and look forward to continuing to support Veracode as it enters its next phase of growth in partnership with TA.”
“We are committed to our mission, strategy, and product vision,” continued King, “and we are excited to partner with TA, leveraging its significant experience investing in enterprise software companies and track record in scaling growth businesses, to realize that vision. We plan to invest in the expansion of our product portfolio through organic development and strategic M&A, as well as accelerate the expansion of our global footprint and growth, while maintaining the healthy business fundamentals we have achieved over the last few years.”
Continued expansion of Veracode’s talented team around the world is central to its growth objectives. The company is hiring talent in engineering, product management, marketing, sales, and customer success. Today, Veracode’s more than 725 team members around the world embrace remote and hybrid work models and are committed to the company’s mission to ensure that the software that powers our world is secure.
Deutsche Bank Securities Inc. is serving as exclusive financial advisor to Veracode and Thoma Bravo, and leading and providing committed debt financing to TA for the transaction. Barclays is serving as financial advisor to TA. Kirkland & Ellis is acting as legal counsel to Thoma Bravo and Goodwin Procter is serving as legal counsel to TA.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com , on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. All other brand names, product names, or trademarks are the property of their respective holders.
About TA Associates
TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – the firm invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 550 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com .
About Thoma Bravo
Thoma Bravo is one of the largest private equity firms in the world, with more than $91 billion in assets under management as of September 30, 2021. The firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging the firm's deep sector expertise and proven strategic and operational capabilities, Thoma Bravo collaborates with its portfolio companies to implement operating best practices, drive growth initiatives and make accretive acquisitions intended to accelerate revenue and earnings. Over the past 20 years, the firm has acquired or invested in more than 350 companies representing over $155 billion in enterprise value. The firm has offices in Chicago, Miami and San Francisco. For more information, visit www.thomabravo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005831/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
